Healthcare provider profile · identity verified

Michael R Mason, MD

Family Practice · ADA, OK · NPI 1821076126

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Losartan Potassium	Losartan Potassium	500	65
Omeprazole	Omeprazole	474	56
Montelukast Sodium	Montelukast Sodium	395	48
Synthroid	Levothyroxine Sodium	394	39
Amlodipine Besylate	Amlodipine Besylate	380	47
Rosuvastatin Calcium	Rosuvastatin Calcium	350	41
Pantoprazole Sodium	Pantoprazole Sodium	308	37
Duloxetine Hcl	Duloxetine Hcl	288	43
Gabapentin	Gabapentin	286	40
Atorvastatin Calcium	Atorvastatin Calcium	284	33
Spironolactone	Spironolactone	264	37
Metformin Hcl Er	Metformin Hcl	251	33
Metoprolol Succinate	Metoprolol Succinate	191	22
Fluticasone Propionate	Fluticasone Propionate	189	32
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	183	26
Ozempic	Semaglutide	180	22
Famotidine	Famotidine	172	24
Eliquis	Apixaban	155	17
Carvedilol	Carvedilol	151	15
Lisinopril	Lisinopril	149	21
Pravastatin Sodium	Pravastatin Sodium	141	15
Sucralfate	Sucralfate	137	16
Glipizide Er	Glipizide	132	24
Ezetimibe	Ezetimibe	128	17
Jardiance	Empagliflozin	128	19
Tamsulosin Hcl	Tamsulosin Hcl	111	12
Albuterol Sulfate Hfa	Albuterol Sulfate	104	20
Furosemide	Furosemide	104	16
Diclofenac Sodium	Diclofenac Sodium	102	23
Meloxicam	Meloxicam	102	22
Azelastine Hcl	Azelastine Hcl	100	13
Finasteride	Finasteride	96	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	95	18
Baclofen	Baclofen	93	15
Clopidogrel	Clopidogrel Bisulfate	88	11
Potassium Chloride	Potassium Chloride	88	16
Chlorthalidone	Chlorthalidone	84	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	82	11
Glipizide Xl	Glipizide	81	23
Pioglitazone Hcl	Pioglitazone Hcl	69	11
Sertraline Hcl	Sertraline Hcl	65	suppressed
Alogliptin	Alogliptin Benzoate	59	11
Colestipol Hcl	Colestipol Hcl	59	suppressed
Celecoxib	Celecoxib	56	suppressed
Ramelteon	Ramelteon	55	suppressed
Allopurinol	Allopurinol	53	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	53	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	52	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	52	suppressed
Valsartan	Valsartan	51	suppressed
Xarelto	Rivaroxaban	51	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	49	suppressed
Clonidine Hcl	Clonidine Hcl	48	suppressed
Spiriva Respimat	Tiotropium Bromide	48	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	46	suppressed
Imipramine Hcl	Imipramine Hcl	46	suppressed
Buspirone Hcl	Buspirone Hcl	45	suppressed
Memantine Hcl	Memantine Hcl	44	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	42	suppressed
Ibuprofen	Ibuprofen	41	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	40	suppressed
Sitagliptin	Sitagliptin	38	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	37	suppressed
Mirtazapine	Mirtazapine	36	suppressed
Flecainide Acetate	Flecainide Acetate	34	suppressed
Torsemide	Torsemide	34	suppressed
Trazodone Hcl	Trazodone Hcl	34	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	33	suppressed
Liothyronine Sodium	Liothyronine Sodium	31	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	29	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	28	suppressed
Atenolol	Atenolol	26	suppressed
Ipratropium Bromide	Ipratropium Bromide	26	suppressed
Prednisone	Prednisone	26	19
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	25	suppressed
Premarin	Estrogens, Conjugated	25	suppressed
Methotrexate	Methotrexate Sodium	24	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	23	14
Sumatriptan Succinate	Sumatriptan Succinate	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Testosterone	Testosterone	22	suppressed
Clonidine	Clonidine	21	suppressed
Fosinopril Sodium	Fosinopril Sodium	21	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	21	suppressed
Tramadol Hcl	Tramadol Hcl	21	suppressed
Acarbose	Acarbose	20	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	suppressed
Entresto	Sacubitril/Valsartan	20	suppressed
Metronidazole	Metronidazole	20	suppressed
Asmanex	Mometasone Furoate	18	suppressed
Bupropion Xl	Bupropion Hcl	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Ondansetron Odt	Ondansetron	18	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	18	suppressed
Naproxen	Naproxen	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	11
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	16	suppressed
Linzess	Linaclotide	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	15	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	15	suppressed
Novolog	Insulin Aspart	15	suppressed
Metformin Hcl	Metformin Hcl	14	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Digoxin	Digoxin	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Lactulose	Lactulose	12	suppressed
Letrozole	Letrozole	12	suppressed
Mesalamine Er	Mesalamine	12	suppressed
Primidone	Primidone	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Folic Acid	Folic Acid	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error